Whenever a hot sector comes under some near-term pressure, the shorts - investors who essentially bet a stock will go down - come out to play. They're not always right or even well-meaning in their intentions. But not all of them are wrong, either.
Where stocks trade typically tells you a lot about how established a company is. It says something about the kind of resources the company has to report to regulators and its developed financial strength. But many of cannabis' greatest opportunities are not on the NYSE or Nasdaq.
Whether a first time trader or a somewhat seasoned investor who just wants to make sure the information they believe is accurate about trading actually is, there is always value in reviewing the basics of cannabis investing and the tools available.
As alcohol Prohibition ended 86 years ago today, illicit revenue became legal profits available to savvy investors, a flood of researched-based innovation drove new products, and the industry soared. This is all happening in the cannabis industryright now.
Epidolex may be the first FDA-approved, cannabis-based pharma product on the market. But over-the-counter, hemp-based CBD products will take a large bite out of that market as it continues to show similar effects as the price, prescription-based brand.
Not all IPOs are created equal. The biggest winners, the next Tilray, are going to thrive in at least one of three key areas of focus. These are areas where companies can truly differentiate themselves from the crowd.
It's difficult to see a stock you recently bought go down. But as those who sold during Canopy Growth's three significant declines dating back to 2015 would attest, now is not the time to lose our resolve.
With 2019 right around the corner, three key themes stand out far beyond any other topics that will shape the business end of the marijuana industry. That includes perhaps the most shocking emerging target demographic for cannabis to date.